GT Biopharma Inc
NASDAQ:GTBP

Watchlist Manager
GT Biopharma Inc Logo
GT Biopharma Inc
NASDAQ:GTBP
Watchlist
Price: 0.8 USD -2.08% Market Closed
Market Cap: 8.5m USD

GT Biopharma Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

GT Biopharma Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
GT Biopharma Inc
NASDAQ:GTBP
Cash from Operating Activities
-$11.4m
CAGR 3-Years
14%
CAGR 5-Years
-30%
CAGR 10-Years
-12%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

GT Biopharma Inc
Glance View

Market Cap
8.5m USD
Industry
Biotechnology

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in Brisbane California, California and currently employs 8 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The firm's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The firm is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).

GTBP Intrinsic Value
0.24 USD
Overvaluation 70%
Intrinsic Value
Price

See Also

What is GT Biopharma Inc's Cash from Operating Activities?
Cash from Operating Activities
-10.9m USD

Based on the financial report for Mar 31, 2025, GT Biopharma Inc's Cash from Operating Activities amounts to -10.9m USD.

What is GT Biopharma Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-12%

Over the last year, the Cash from Operating Activities growth was -8%. The average annual Cash from Operating Activities growth rates for GT Biopharma Inc have been 14% over the past three years , -30% over the past five years , and -12% over the past ten years .

Back to Top